Proteomics International Laboratories Investor Relations Material

Proteomics International Laboratories Ltd is an Australian life sciences company specializing in predictive diagnostics and analytical services based on proteomics, the study of proteins. The company develops diagnostic tests for chronic diseases, with a focus on its flagship product, PromarkerD, a predictive test for diabetic kidney disease. In addition to diagnostics, Proteomics International provides contract research services, including protein analysis, biomarker discovery, and pharmaceutical testing, supporting drug development and medical research. Proteomics International Laboratories Ltd is headquartered in Perth, Australia, and its shares are listed on the ASX.